COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • BACKGROUND: GENCOV is a prospective, observational cohort study of COVID-19-positive adults. Here, we characterize and compare side effects between COVID-19 vaccines and determine whether reactogenicity is exacerbated by prior SARS-CoV-2 infection. METHODS: Participants were recruited across Ontario, Canada. Participant-reported demographic and COVID-19 vaccination data were collected using a questionnaire. Multivariable logistic regression was performed to assess whether vaccine manufacturer, type, and previous SARS-CoV-2 infection are associated with reactogenicity. RESULTS: Responses were obtained from n = 554 participants. Tiredness and localized side effects were the most common reactions across vaccine doses. For most participants, side effects occurred and subsided within 1-2 days. Recipients of Moderna mRNA and AstraZeneca vector vaccines reported reactions more frequently compared to recipients of a Pfizer-BioNTech mRNA vaccine. Previous SARS-CoV-2 infection was independently associated with developing side effects. CONCLUSIONS: We provide evidence of relatively mild and short-lived reactions reported by participants who have received approved COVID-19 vaccines.

authors

  • Morgan, Gregory
  • Casalino, Selina
  • Chowdhary, Sunakshi
  • Frangione, Erika
  • Fung, Chun Yiu Jordan
  • Lapadula, Elisa
  • Arnoldo, Saranya
  • Bearss, Erin
  • Binnie, Alexandra
  • Borgundvaag, Bjug
  • Briollais, Laurent
  • Dagher, Marc
  • Devine, Luke
  • Friedman, Steven M
  • Khan, Zeeshan
  • Mighton, Chloe
  • Nirmalanathan, Konika
  • Richardson, David
  • Stern, Seth
  • Taher, Ahmed
  • Wolday, Dawit
  • Lerner-Ellis, Jordan
  • Taher, Jennifer

publication date

  • April 2024